PROCEPT BioRobotics Corporation faces securities class-action litigation over alleged misstatements and omissions concerning sales of its single-use handpiece, a component of its Aquablation therapy for patients with an enlarged prostate. Rosen Law Firm reminded investors who purchased PROCEPT common stock between February 28, 2024, and February 25, 2026, of a September 22, 2026, deadline to seek lead-plaintiff appointment. The allegations center on an undisclosed discount program that allegedly encouraged bulk orders beyond procedural demand, pulled sales and revenue forward, and contributed to more than 10,000 excess handpieces in customer inventories by the end of the Class Period. PROCEPT reported weaker-than-expected handpiece sales on August 6, 2025, and November 4, 2025, before disclosing on February 25, 2026, that U.S. sales had exceeded procedures in every quarter since the first quarter of 2023. U.S. quarterly sales fell to 9,400 units from 13,225, while shares declined $22.06, or more than 48%, from the August 6, 2025, close. Hagens Berman and Pomerantz had previously announced related litigation. No class has been certified, and investors may remain absent class members without taking action at this stage.